LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Prothena Corp PLC

Fermé

SecteurSoins de santé

5.39 6.52

Résumé

Variation du prix de l'action

24h

Actuel

Min

5.01

Max

5.43

Chiffres clés

By Trading Economics

Revenu

-2.2M

-60M

Ventes

705K

2.8M

BPA

-1.12

Marge bénéficiaire

-2,128.536

Employés

163

EBITDA

-682K

-65M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+380.04% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-495M

251M

Ouverture précédente

-1.13

Clôture précédente

5.39

Sentiment de l'Actualité

By Acuity

50%

50%

167 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Prothena Corp PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 juin 2025, 20:45 UTC

Résultats

Broadcom 2Q Sales Climb on Booming AI Demand

5 juin 2025, 23:45 UTC

Market Talk

Nikkei May Decline as Caution Over U.S. Economy Continues -- Market Talk

5 juin 2025, 23:44 UTC

Market Talk

Gold Edges Higher on Weak U.S. Data -- Market Talk

5 juin 2025, 23:30 UTC

Market Talk

NZME Cost Cuts Can Cushion Effect of Weak Market -- Market Talk

5 juin 2025, 21:32 UTC

Résultats

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 juin 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

5 juin 2025, 20:45 UTC

Résultats

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 juin 2025, 20:24 UTC

Résultats

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 juin 2025, 20:15 UTC

Résultats

Broadcom 2Q Cont Ops EPS $1.03 >AVGO

5 juin 2025, 20:15 UTC

Résultats

Broadcom 2Q Rev $15B >AVGO

5 juin 2025, 20:15 UTC

Résultats

Broadcom 2Q Net $4.97B >AVGO

5 juin 2025, 20:15 UTC

Résultats

Broadcom 2Q Adj EPS $1.58 >AVGO

5 juin 2025, 20:15 UTC

Résultats

Broadcom 2Q EPS $1.03 >AVGO

5 juin 2025, 20:15 UTC

Résultats

Broadcom Sees 3Q Rev $15.8B >AVGO

5 juin 2025, 20:11 UTC

Acquisitions, Fusions, Rachats

Constellation Energy: Transaction Is Expected to Close in the 4Q >CEG

5 juin 2025, 20:11 UTC

Acquisitions, Fusions, Rachats

Constellation Energy: Calpine Deal Clears Texas Regulatory Review

5 juin 2025, 20:11 UTC

Acquisitions, Fusions, Rachats

Constellation Energy: With Approval From PUCT Secured, Transaction Awaits Clearance From NY State Public Service Commission, Federal Energy Regulatory Commission and DOJ >CEG

5 juin 2025, 19:22 UTC

Market Talk

Oil Futures Resume Upward Moves -- Market Talk

5 juin 2025, 19:00 UTC

Market Talk

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

5 juin 2025, 18:32 UTC

Market Talk

Gold Slips After Trump-Xi Call -- Market Talk

5 juin 2025, 18:26 UTC

Résultats

These Stocks Are Moving the Most Today: Broadcom, Tesla, Circle, Brown-Forman, MongoDB, Planet Labs, ChargePoint, Ciena, and More -- Barrons.com

5 juin 2025, 18:06 UTC

Market Talk

Transpacific Ship Freight Rates Spike on China Tariff Truce -- Market Talk

5 juin 2025, 16:30 UTC

Acquisitions, Fusions, Rachats

Vallourec Completes The Acquisition Of Thermotite Do Brasil >VK.FR

5 juin 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

5 juin 2025, 16:18 UTC

Market Talk

U.S. Natural Gas Market Shrugs Off Big Storage Build -- Market Talk

5 juin 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 juin 2025, 16:12 UTC

Market Talk

Global Energy Roundup: Market Talk

5 juin 2025, 16:12 UTC

Market Talk

Copper Prices Rise on Positive Signals From Trump on China Trade Talks -- Market Talk

5 juin 2025, 16:03 UTC

Market Talk

U.S. Diesel, Gasoline Futures Pick Back Up -- Market Talk

5 juin 2025, 15:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Comparaison

Variation de prix

Prothena Corp PLC prévision

Objectif de Prix

By TipRanks

380.04% hausse

Prévisions sur 12 Mois

Moyen 24.29 USD  380.04%

Haut 81 USD

Bas 4 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

9 ratings

4

Achat

4

Maintien

1

Vente

Score Technique

By Trading Central

N/A / 7.35Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Very Strong Bearish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

167 / 380Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.